A company has trained an ML model primarily using synthetic data, and now intends to use live personal data to test the model.
Which of the following is NOT a best practice apply during the testing?
During the first month when the company monitors the model for bias, it is most important to?
The best method to ensure a comprehensive identification of risks for a new AI model is?
After completing model testing and validation, which of the following is the most important step that an organization takes prior to deploying the model into production?
You are the chief privacy officer of a medical research company that would like to collect and use sensitive data about cancer patients, such as their names, addresses, race and ethnic origin, medical histories, insurance claims, pharmaceutical prescriptions, eating and drinking habits and physical activity.
The company will use this sensitive data to build an Al algorithm that will spot common attributes that will help predict if seemingly healthy people are more likely to get cancer. However, the company is unable to obtain consent from enough patients to sufficiently collect the minimum data to train its model.
Which of the following solutions would most efficiently balance privacy concerns with the lack of available data during the testing phase?
Your organization is searching for a new way to help accurately forecast sales predictions by various types of customers.
Which of the following is the best type of model to choose if your organization wants to customize the model and avoid lock-in?
All of the following types of testing can help evaluate the performance of a responsible Al system EXCEPT?
All of the following are potential benefits of using private over public LLMs EXCEPT?
Which of the following use cases would be best served by a non-AI solution?
Which of the following is an obligation of an importer of high-risk AI systems under the EU AI Act?